Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (DE:PGF)
BERLIN:PGF
RESEARCH TOOLSreports
Protagonist Therapeutics (PGF) Stock Price & Analysis
1 Followers
PGF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€12.60 - €31.20
Previous Close€29.2
Volume0.00
Average Volume (3M)N/A
Market Cap
€1.73B
Enterprise Value€1.41B
Total Cash (Recent Filing)$341.63M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)N/A
Beta0.93
Next Earnings
Aug 01, 2024EPS Estimate
-€0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,652,133
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.16
Price to Sales (P/S)18.01
Price to Cash Flow (P/CF)25.60
P/FCF Ratio25.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.51
Enterprise Value/Gross Profit23.51
Enterprise Value/Ebitda-17.58
Forecast
1Y Price Target
€38.40Price Target Upside31.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Protagonist Therapeutics News
PremiumStock Analysis & Ideas
3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
54.17% Other Institutional Investors
45.83% Public Companies and
Individual Investors
PGF FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was €12.60 and its highest was €31.20 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Currently, no data Available
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on May 08, 2024. The company reported €3.012 earnings per share for the quarter, missing the consensus estimate of €3.111 by -€0.099.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -€0.55.
How many shares outstanding does Protagonist Therapeutics have?
Currently, no data Available
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of €3.012 in its last earnings report, missing expectations of €3.111. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 131M.
---
Protagonist Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€38.40 (31.49% Upside)
€38.40 (31.49% Upside)
Blogger Sentiment
Bullish
DE:PGF Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $783.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.74%
12-Months-Change
Fundamentals
Return on Equity
41.75%
Trailing 12-Months
Asset Growth
162.35%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PGF Stock 12 Month Forecast
Average Price Target
€38.40
▲(31.49% Upside)
Technical Analysis
Protagonist Therapeutics
―
Aileron Therapeutics
―
Aldeyra Therapeutics
―
Aptose Biosciences
―
Agenus
―
Best Analysts Covering PGF
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+61.89%
reiterated a buy rating 9 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +61.89% per trade.
---